Novo Nordisk A/S (NVO) Shares Outstanding: 4.45
Is Novo Nordisk A/S’s shares outstanding high or low?
Novo Nordisk A/S's shares outstanding of 4.45 is in line with its 5-year average of 4.53, near the low end of its 5-year range (4.45–4.67).
0.07% below its 12-month average of 4.45.
NVO Shares Outstanding Chart
NVO Average Shares Outstanding Chart
NVO Current vs Average Shares Outstanding Chart
NVO Shares Outstanding Metrics
SHARES OUTSTANDING
4.45
SHARES OUTSTANDING AVG TTM
4.45
SHARES OUTSTANDING AVG 3Y
4.48
SHARES OUTSTANDING AVG 5Y
4.53
SHARES OUTSTANDING AVG 10Y
4.72
SHARES OUTSTANDING AVG 15Y
4.97
SHARES OUTSTANDING AVG 20Y
5.29
CURRENT VS TTM AVG
-0.07%
CURRENT VS 3Y AVG
-0.69%
CURRENT VS 5Y AVG
-1.80%
CURRENT VS 10Y AVG
-5.81%
CURRENT VS 15Y AVG
-10.52%
CURRENT VS 20Y AVG
-15.86%
Share Structure
Shares Outstanding
4.45B
Float Shares
N/A
Stock Price
$43.52
Market Cap
$193.4B
Annual Shares Outstanding History
| Year | Weighted Average Shares | YoY Change |
|---|---|---|
| 2025 | 4.45B | -0.14% |
| 2024 | 4.45B | -0.64% |
| 2023 | 4.48B | -1.06% |
| 2022 | 4.53B | -1.36% |
| 2021 | 4.59B | -1.60% |
| 2020 | 4.67B | -1.70% |
| 2019 | 4.75B | -1.87% |
| 2018 | 4.84B | -2.34% |
| 2017 | 4.96B | -2.25% |
| 2016 | 5.07B | -1.67% |
| 2015 | 5.16B | -1.98% |
| 2014 | 5.26B | -2.37% |
| 2013 | 5.39B | -1.76% |
| 2012 | 5.48B | -3.02% |
| 2011 | 5.65B | -2.60% |
| 2010 | 5.81B | -3.12% |
| 2009 | 5.99B | -3.02% |
| 2008 | 6.18B | -2.08% |
| 2007 | 6.31B | -1.77% |
| 2006 | 6.42B | -2.19% |
| 2005 | 6.57B | -2.89% |
| 2004 | 6.76B | -1.01% |
| 2003 | 6.83B | -1.40% |
| 2002 | 6.93B | +0.61% |
| 2001 | 6.89B | -0.55% |
| 2000 | 6.92B | -1.36% |
| 1999 | 7.02B | -4.49% |
| 1998 | 7.35B | -2.48% |
| 1997 | 7.54B | +0.88% |
| 1996 | 7.47B | - |
Relationship: Market Cap = Shares Outstanding × Stock Price
Key concepts:
- Float shares: Shares available for public trading
- Dilution: When new shares are issued, existing shareholders own less
- Buybacks: Reduce share count, increasing EPS and ownership stake
- Stock splits: Increase share count but don't change market cap
Novo Nordisk A/S Shares Outstanding Formula & Definition
Shares Outstanding represents the total number of shares issued by a company that are held by all shareholders. Changes in share count affect EPS and ownership dilution.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Novo Nordisk A/S Shares Outstanding FAQ
- What is the shares outstanding for Novo Nordisk A/S (NVO)?
- The shares outstanding for NVO stock is 4.45.
- Is Novo Nordisk A/S's shares outstanding high or low?
- Novo Nordisk A/S's shares outstanding of 4.45 is in line with its 5-year average of 4.53, near the low end of its 5-year range (4.45–4.67).
- What is the TTM average shares outstanding for Novo Nordisk A/S (NVO)?
- The TTM average shares outstanding for NVO stock is 4.45.
- What is the 3Y average shares outstanding for Novo Nordisk A/S (NVO)?
- The 3Y average shares outstanding for NVO stock is 4.48.
- What is the 5Y average shares outstanding for Novo Nordisk A/S (NVO)?
- The 5Y average shares outstanding for NVO stock is 4.53.
- What is the 10Y average shares outstanding for Novo Nordisk A/S (NVO)?
- The 10Y average shares outstanding for NVO stock is 4.72.
- What is the 15Y average shares outstanding for Novo Nordisk A/S (NVO)?
- The 15Y average shares outstanding for NVO stock is 4.97.
- What is the 20Y average shares outstanding for Novo Nordisk A/S (NVO)?
- The 20Y average shares outstanding for NVO stock is 5.29.
Novo Nordisk A/S Shares Outstanding History
| DATE | SHARES OUTSTANDING |
|---|---|
| 2025-12-31 | 4.45 |
| 2024-12-31 | 4.45 |
| 2023-12-31 | 4.48 |
| 2022-12-31 | 4.53 |
| 2021-12-31 | 4.59 |
| 2020-12-31 | 4.67 |
| 2019-12-31 | 4.75 |
| 2018-12-31 | 4.84 |
| 2017-12-31 | 4.96 |
| 2016-12-31 | 5.07 |
| 2015-12-31 | 5.16 |
| 2014-12-31 | 5.26 |
| 2013-12-31 | 5.39 |
| 2012-12-31 | 5.48 |
| 2011-12-31 | 5.65 |
| 2010-12-31 | 5.81 |
| 2009-12-31 | 5.99 |
| 2008-12-31 | 6.18 |
| 2007-12-31 | 6.31 |
| 2006-12-31 | 6.42 |
| 2005-12-31 | 6.57 |
| 2004-12-31 | 6.76 |
| 2003-12-31 | 6.83 |
| 2002-12-31 | 6.93 |
| 2001-12-31 | 6.89 |
| 2000-12-31 | 6.92 |
| 1999-12-31 | 7.02 |
| 1998-12-31 | 7.35 |
| 1997-12-31 | 7.54 |
| 1996-12-31 | 7.47 |
Related Metrics
About Novo Nordisk A/S
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care division delivers therapies for diabetes, obesity, cardiovascular ailments, and other emerging therapeutic areas. Meanwhile, the Rare Disease division concentrates on providing treatments for rare blood disorders, uncommon endocrine conditions, and hormone replacement solutions. In addition to its core pharmaceutical offerings, Novo Nordisk produces specialized medical equipment such as insulin pens, growth hormone pens, and injection needles. It also pioneers smart digital solutions for diabetes management, including advanced insulin pens and the Dose Check application, designed to guide insulin dosage. The company engages in strategic alliances, notably a partnership with UNICEF to combat childhood obesity and a collaboration with Valo Health, Inc. to discover and advance novel drug pipelines in the cardiometabolic space. Founded in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Maziar Mike Doustdar